Serge Berger

Serge Berger

InvestorPlace Contributor

Serge Berger is the Head Trader and Investment Strategist for The Steady Trader.

He has been an active trader since 1998. During his career, he has been a financial analyst, dealt in fixed income instruments at JPMorgan, and was a proprietary trader in equity options and futures. Having exposure to a range of different asset classes allowed him to identify which asset classes and strategies best fit his goal of achieving consistent profits.

Over the years, he created a trading methodology that divides markets into different time frames and characters, allowing him to determine which strategies to apply in which situations without emotion. By focusing on only the highest probability trading setups, Serge maximizes overall profitability and minimizes stress and volatility.

Follow him on Twitter via @SteadyTrader.

Recent Articles

Trade of the Day: Deere Stock Looks Ready to Truck Higher

By Serge Berger, InvestorPlace Contributor

Industrial stocks are still struggling, but DE stock has given the bulls four bullish reversals since late April and looks increasingly likely to push higher.

Trade of the Day: Square Stock Is Out Over Its Skis

By Serge Berger, InvestorPlace Contributor

While the underlying growth story in Square may remain intact, SQ stock on the charts is increasingly at risk of a mean-reversion move lower.

Trade of the Day: Is Alphabet Next to Break Out?

By Serge Berger, InvestorPlace Contributor

GOOGL stock, while lifting in recent days, has yet to break out past its summer highs. Alphabet could thus be next on the list of breakout candidates.

Trade of the Day: Celgene Is Coiling Up for a Rally

By Serge Berger, InvestorPlace Contributor

Biotechnology stocks have started to wake up, and Celgene looks primed to rally. CELG stock is at a key moving average, and a push above it could bring more buyers.

Trade of the Day: Amgen Is a Strong Stock in a Giddy Industry

By Serge Berger, InvestorPlace Contributor

AMGN stock has seen a steady incline since May and one that has good odds of continuing. This is sponsored by a general bid in the healthcare and biotechnology sectors.

Load More